

Design, Synthesis and Biological Evaluation of Novel Phenothiazines for Cancer Exploring through Anti-Oxidant and Anti-Inflammatory Activities

Abhilasha Dara^{1*}, I. Supriya², Sk. Aneesa³, K. Chennakesava⁴, P. Sindhu⁵¹Assistant Professor, Department of Pharmaceutical Chemistry, Hindu College of Pharmacy, Guntur, India²Assistant Professor, Department of Pharmaceutical Chemistry, Nirmala College of Pharmacy, Mangalagiri, Guntur, India^{3,4,5}Students of Hindu College of Pharmacy, Guntur, IndiaDOI: <https://doi.org/10.36347/sajp.2024.v13i10.002>

| Received: 04.11.2024 | Accepted: 10.12.2024 | Published: 16.12.2024

*Corresponding author: Abhilasha Dara

Assistant Professor, Department of Pharmaceutical Chemistry, Hindu College of Pharmacy, Guntur, India

Abstract

Original Research Article

Cancer is defined as development of number of abnormal cells by uncontrollable cell division leads to the tissue detriment. It has the ability to spread throughout the body. Cancer is second-leading disease to cause the death in the world. Now-a-days survival rate for cancer may increase through the treatment. In this study, the cancer is treated by exploring the anti-oxidant and anti-inflammatory activity of novel Phenothiazines. Because anti-oxidants play a vital role in treatment of cancer by reducing the oxidative stress, abnormal cell division reduction, decrease in DNA damage, and reduced mutagenesis. As we know that NSAIDS (anti-inflammatory drugs) can help in prevention of cancer by inhibiting COX enzyme, increasing apoptosis, reducing cell migration, increasing chemo-sensitivity. Through this study we proved the anti-oxidant and anti-inflammatory activity of newly synthesized phenothiazine derivatives, followed by anti-cancer activity in addition with *in-silico* molecular docking studies to explore the exact mechanism of action of phenothiazine in cancer treatment.

Keywords: Phenothiazines, anti-oxidant, anti-inflammatory, anti-cancer activity, docking studies.

Copyright © 2024 The Author(s): This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC BY-NC 4.0) which permits unrestricted use, distribution, and reproduction in any medium for non-commercial use provided the original author and source are credited.

1. INTRODUCTION

Cancer is defined as development of number of abnormal cells by uncontrollable cell division leads to the tissue detriment. It can spread throughout the body. Cancer is second-leading disease to cause the death in the world. Now-a-days survival rate for cancer may increase through the treatment. In this study, the cancer is treated by exploring the anti-oxidant and anti-inflammatory activity of novel Phenothiazines.

This study focuses on the repurposing of phenothiazine derivatives in cancer therapy. Many reported studies suggest that anti-oxidants may reduce the oxidative stress by neutralizing the unstable atoms (free radicals) which can damage DNA and cause cancer. Anti-oxidants protect non-cancerous cells and can prevent chemoresistance to improve response to the drugs chemotherapy. Anti-oxidants can also reduce abnormal cell division, and mutagenesis. So, anti-oxidants may be helpful for the cancer treatment.

Anti-inflammatory drugs play a major role in cancer treatment by reducing the inflammation which is a main factor for the development and progression of tumor. These drugs also help to penetrate the immune cells into the cancer cell to destroy them. They can protect the DNA from damage and repair the damaged DNA. These drugs can increase the apoptosis of cancer cells, reduce cell migration, and sensitize the cancer cells for cytotoxic drugs chemotherapy. NSAIDS are the well-known anti-inflammatory drugs that suppress the genes which are activated during the inflammation and progression of cancer. They act by inhibiting the cyclooxygenase enzyme in turn leads to down regulation of VEGF (Vascular Endothelial Growth Factor) and inhibition of PI3K/Akt signaling pathway.

According to structure activity relationship modifications in Phenothiazine nucleus influence the extent of activity. Novel Phenothiazine derivatives were designed by modifying the angular attachments by substituting with different halogen derivatives. In this study we try to prove the exact mechanism of action of

novel phenothiazine derivatives through molecular docking studies. *In-silico* molecular docking studies may be helpful for the development of more potent derivatives by reducing the time and cost for drug discovery process.

2. EXPERIMENTAL

2.1 INSTRUMENTS

All chemicals were purchased from Empire scientific chemical companies for synthesis. The melting point was observed in open glass capillaries on the mettler FP51 melting point apparatus. The IR spectrum peaks provide insight into the probable structure of the corresponding IR region ranges between 4000-666 cm⁻¹. Quanta radiation from this spectrum region corresponds to energy difference between various vibrational levels of molecules. The compounds were recorded on BRUKER FTIR-8400S spectrophotometer shows different vibrational levels of molecules. The ¹H NMR and ¹³C NMR spectra enable us to know different chemical and magnetic environments corresponding to protons and carbons in molecule. The samples were analysed on BRUKER 100MHz spectrometer.

2.2 General synthesis

Step :1 General procedure for the preparation of 7,8or9 substituted aniline Aldehyde derivative- Equimolar amount of substituted aniline was added to a chlorobenzaldehyde in 20 ml of DMF and 0.1 percent of potassium hydroxide solution and the reaction mixture was heated under reflux at about 80°C temperature, for 2 h. TLC indicated the end of reaction. The mixture was cooled by addition of a water /ice mixture. The solid was filtered I excellent yield.

Step:2 General procedure for the preparation of 7,8or9 substituted 10H phenothiazine 1 benzaldehyde derivative -II -Equimolar amount of 7,8or9 substituted Aniline benzaldehyde was added to a solution of sulphur powder and iodine in 5ml of ethanol. Reaction mixture was heated under reflux with stirring for about 2 h and poured into ice/water mixture. the precipitation was filtered and washed with cold water.

2.3 2-nitro-10,10a-dihydro-4aH-phenothiazine-9-carbaldehyde (PTZ-1)- A mixture of chlorobenzaldehyde 14.05gms and 2-nitro aniline 13.81gms in 20ml of KOH and 20 ml of Di methyl formamide was added by stirring, thus mixture was heated under reflex condenser for 2 hrs, then the mixture was cooled by addition of ice. The residue was filtered and dried. 7,8or9 substituted aniline Aldehyde derivative was formed. To the 7,8or9 substituted aniline Aldehyde derivative was added to a solution or sulphur 3.2 gms and iodine 1.26 gms in 5 -10 ml of ethanol by stirring. the mixture was heated under reflex condenser for 2 hrs. the mixture is poured in a ice /water. The residue is filtered and dried at room temperature. 2-nitro-10,10a-dihydro-4aH-phenothiazine-9-carbaldehyde PTZ-1 was formed, percentage yield:63%. ¹H NMR (400Hz, DMSO), PTZ-1 δ6.5(CHO), δ2.0, δ6.0(N-H), ¹³C PTZ-1 δ113(C-N).

(C=O), δ2.0, δ6.0(C-S), Mass Spectroscopy(m/z): 250.503, IR: C-H (alkane)-2937.29, C-H (aromatic)-837, C=C (aromatic)-2149.33, C= O (ester)-, C=O (acid)-1707.4, C=O (amide)-,N-H(s)-1590.44, N-O(B)-1490, S-H(S)-2563.06, C-F(B):1330, C-C(S):746.37, C=N(B):1635.6, C=S(S):1184.05, C=S(B):1333.50 Interaction Residues: APG:73, TYR:409, TYR:472, PHE:480, ASN:575, LYS:501 Estimated of free energy binding: -8.9kcal/mol.

2.4 3-nitro-10,10a-dihydro-4aH-phenothiazine-9-carbaldehyde (PTZ-2)- A mixture of chlorobenzaldehyde 14.05gms and 3-nitro aniline 13.81gms in 20ml of KOH and 20 ml of Di methyl formamide was added by stirring, thus mixture was heated under reflex condenser for 2 hrs, then the mixture was cooled by addition of ice. the residue was filtered and dried. 7,8or9 substituted aniline Aldehyde derivative was formed. To the 7,8or9 substituted aniline Aldehyde derivative was added to a solution or sulphur 3.2 gms and iodine 1.26 gms in 5 -10 ml of ethanol by stirring. the mixture was heated under reflex condenser for 2 hrs. the mixture is poured in a ice /water. The residue is filtered and dried at room temperature. 3-nitro-10,10a-dihydro-4aH-phenothiazine-9-carbaldehyde PTZ-2 yield-63, ¹H NMR (400Hz, DMSO), PTZ-2 δ6.5(CHO), δ2.0, δ6.0(N-H), ¹³C PTZ-2 δ6.5(C=O), δ2.0, δ6.0(C-N) Mass spectroscopy m/z: 248.504 IR: , C-H (aromatic)-849, C=C (aromatic)-1653.59, C=O (ester)-1592.91, C=O(acid)-1711.75, C=O (amide)-1695.03, N-H(s)-1592.44, N-O(B)-1592.1., C-F(B):1488, C- C(S):746.37, C=N(B):1635.6, C=S(S):1184.05, C=S(B):11283. Interaction Residues: ASN;493, PHE;480, LYS;501, TYR;472 Estimated of free energy binding: -8.9kcal/mol.

2.5 4-chloro-10,10a-dihydro-4aH-phenothiazine-9-carbaldehyde (PTZ-3)- A mixture of chlorobenzaldehyde 14.05gms and 4-chloro aniline 13.81gms in 20ml of KOH and 20 ml of Di methyl formamide was added by stirring, thus mixture was heated under reflex condenser for 2 hrs, then the mixture was cooled by addition of ice. The residue was filtered and dried. 7,8or9 substituted aniline Aldehyde derivative was formed. To the 7,8or9 substituted aniline Aldehyde derivative was added to a solution or sulphur 3.2 gms and iodine 1.26 gms in 5 -10 ml of ethanol by stirring. the mixture was heated under reflex condenser for 2 hrs. the mixture is poured in a ice /water. The residue is filtered and dried at room temperature. 4-chloro-10,10a-dihydro-4aH-phenothiazine 9 carbaldehyde yield-85%. ¹H NMR (400Hz, DMSO), PTZ-3 δ5.5, CHO δ3.0 N-H δ6. ¹³C PTZ-3 δ5.5, C=O δ3.0 N-H δ6.0, Mass Spectroscopy m/z:158.446, IR: C-H (alkane)-2937.29, C-H (aromatic)-837, C=C (aromatic)-2149.33, C= O (ester)-, C=O (acid)-1707.4, C=O (amide)-1085.27, N-H(s)-1649.92, N-O(B)-1592.88, C-F(B):1396.60, C C(S):799.6, C=N(B):1685.6, C=S(S):1192.32, C=S(B):1396 Interaction Residues: ALA;411, TYR;472,

PHE;480; ASN;575 Estimated of free energy binding: -8.6kcal/mol.


2.6 3-chloro-4-fluoro-10, dihydro-4aH-phenothiazine-carbaldehyde (PTZ-3)-A mixture of chlorobenzaldehyde 14.05gms and 3-chloro-4-fluoro aniline 13.81gms in 20ml of KOH and 20 ml of Di methyl formamide was added by stirring, thus mixture was heated under reflux condenser for 2 hrs, then the mixture was cooled by addition of ice The residue was filtered and dried. 7,8or9 substituted aniline Aldehyde derivative was formed.

To the 7,8or9 substituted aniline Aldehyde derivative was added to a solution of sulphur 3.2 gms and iodine 1.26 gms in 5 -10 ml of ethanol by stirring. the mixture was heated under reflux condenser for 2 hrs. The mixture is poured in a ice /water. The residue is filtered and dried at room temperature 3-chloro-4-fluoro-10, dihydro-4aH-phenothiazine-carbaldehyde (PTZ-3), yield-80% .1H NMR (400Hz, DMSO), PTZ-4 CHO δ 6.0, N-H δ 6.6 .1C13 PTZ-4 (C=O) δ 6.0, (C-N) δ 6.6 .IR: C-H (alkane)-2975.21, C-H (aromatic)-826.65, C=C (aromatic)-1675.18, C= O (ester)-1585.60, C=O (acid)-1740.9, C=O (amide)-1725.13, N-H(s)-1644.8, N-O(B)-1585.60, C-F(B):1356.53, C-S(S):782.29, C=S(S):1185.71, C=S(B):1356 Spectroscopy m/z: 1185 Interaction Residues: TYR;472, ASN;575, PHE;480 Estimated of free energy binding: -8.7kcal/mol.

2.7 4-fluoro-10,10a-dihydro-4aH-phenothiazine-9-carbaldehyde (PTZ -4)- A mixture of chlorobenzaldehyde 14.05gms and 3-chloro-4-fluoro aniline 13.81gms in 20ml of KOH and 20 ml of Di methyl formamide was added by stirring, thus mixture was heated under reflux condenser for 2 hrs, then the mixture was cooled by addition of ice .the residue was filtered and dried. 7,8or9 substituted aniline Aldehyde derivative was formed.

To the 7,8or9 substituted aniline Aldehyde derivative was added to a solution of sulphur 3.2 gms and iodine 1.26 gms in 5 -10 ml of ethanol by stirring. the mixture was heated under reflux condenser for 2 hrs.the mixture is poured in a ice /water. The residue is filtered and dried at room temperature 4-fluoro-10,10a-dihydro-4aH-phenothiazine-9-carbaldehyde (PTZ -4) yield-89, 1H NMR (400Hz, DMSO), PTZ-5 δ 5.5, CHO δ 3.0 N-H δ 6.0, 1C13 PPTZ-5 (δ 5.5, C=O δ 3.0 C-N δ 6.0). IR: C-H (alkane)-2909.68, C-H:830.34, C-C (aromatic):2170.98, C=C (aromatic)-1587.08, C= O (ester)-1726.50, C=O (acid)-1695.46, C=O (amide)-1637.12, N-H(s)-1695.46, N-O(B)-1511.25, C-F(B):1361.89, C-C(S):776.88, C=N(B):1683.6, C=S(S):1183.77, C=S(B):1361.89. Mass Spectroscopy m/z: 202.346, Interaction Residues: PHE;480, ALA;411, ASN;575 Estimated of free energy binding: -8.6kcal/mol.

3. REACTION SCHEME General Scheme for the Synthesis of the Compounds STEP-1



STEP-2




Table-1: List of synthesized compounds with their IUPAC names






S.N	Compound	Structure	Molecular formula	Molecular weight	Melting point	% yield
1	PTZ-I	 <p>2-nitro-10,10a-dihydro-4aH-phenothiazine-9-carbaldehyde</p>	C ₁₂ H ₈ N ₂ O ₂ S	244.26	95-98	69
2	PTZ-II	 <p>3-nitro-10,10a-dihydro-4aH-phenothiazine-9-carbaldehyde</p>	C ₁₂ H ₈ N ₂ O ₂ S	244.27	97-99	63
3	PTZ-III	 <p>4-chloro-10,10a-dihydro-4aH-phenothiazine-9-carbaldehyde</p>	C ₁₂ H ₈ ClNS	233.72	95-98	85
4	PTZ-IV	 <p>3-chloro-4-fluoro-10,10a-dihydro-4aH-phenothiazine-9-carbaldehyde</p>	C ₁₃ H ₉ ClFNO S	281.73	98-110	80
5	PTZ-V	 <p>4-fluoro-10,10a-dihydro-4aH-phenothiazine-9-carbaldehyde</p>	C ₁₃ H ₁₀ FNOS	247.29	95-120	89

Table-2: IR data for synthesized compounds

Compound code	C-H (alkane)	C-H (aromatic)	C=C (alkene)	C=C (aromatic)	C=O (ester)	C=O (acid)	C=O (amide)	N-H (Stretching)	N-O (Bending)	S-H (Stretching)	C-F (Bending)	C-C (Stretching)	C=N (Bending)	C=S (Stretching)	C=S (Bending)
PT Z-I	2937.29	839.47	1655.69	2149.33	—	1707.4	—	1590.44	1590.44	2563.06	1330.50	746.37	163.5.6	1184.05	1333.50
PT Z-II	—	849.78	1653.59	1592.91	173.4.4	1711.75	1695.03	1617.61	1592.1	—	1488.32	785.63	166.8..8	1183.19	1246.46
PT Z-III	—	823.26	1669.54	1592.88	171.2.5	1712.51	1085.57	1649.72	1592.88	—	1396.60	799.86	168.5.5	1192.32	1396.60
PT Z-IV	2975.21	826.65	1671.18	1585.60	174.0.9	1725.23	1691.74	1644.8	1585.60	2553.16	1356.53	782.29	—	1185.71	1356.53
PT Z-V	2909.68	830.34	2170.98	1587.08	174.9.7	1726.50	1695.46	1637.12	1695.46	2522.15	1361.89	776.88	165.3.6	1183.77	1361.89

Table-3: ¹H-NMR spectral data for synthesized compounds

Compound Code	Nature of Protein	Aromatic Proton	CHO-H	N-H	S-H	Total no. of Protons
PTZ-I	No of proton δValueppm	6 6.5-8.0	1 2.0-2.6	1 5.0-9.0	-	8
PTZ-II	No of proton δValueppm	6 6-8	1 2.8-3.0	1 5.5-8.0	-	8
PTZ-III	No of proton δValueppm	6 5.5-8	1 3.0-3.5	1 6.0-7.6	-	8
PTZ-IV	No of proton δValueppm	5 5.6-7	1 4.0-4.5	1 6.6-7.0	-	7
PTZ-V	No of proton δValueppm	6 6.0-7.0	1 1.5-4	1 7.0-8.0	-	8

Table-3.1: C-NMR spectral data for synthesized compounds

compound code	Nature of protein	aromatic carbon	C-N	C=O	C-S	Total no. of protons
PTZ-I	No of proton δValueppm	9 113.12	1 152.14	1 39.95	1 14.2	12
PTZ-II	No of proton δValueppm	9 112.15	1 161.25	1 39.51	1 28.2	12
PTZ-III	No of proton δValueppm	9 115.02	1 162.45	1 33.45	1 28.3	12
PTZ-IV	No of proton δValueppm	10 116.71	1 160.22	1 38.12	1 16.2	13
PTZ-V	No of proton δValueppm	10 112.3	1 150.4	1 30.15	1 14.2	13

BIOLOGICAL SCREENING:**Table-4: Analysis of molecular docking**

S.No	Compound code	Docking score
1	PTZ-I	-8.9kcal/mol
2	PTZ-II	-8.9kcal/mol
3	PTZ-III	-8.6kcal/mol
4	PTZ-IV	-8.7kcal/mol

5	PTZ-V	-8.6kcal/mol
6	ASPIRIN	-7.2kcal/mol

Table-5: Electronic properties- Mulliken charges

Atom	charge
C (1)	0.302846
C (2)	-0.298885
C (3)	-0.016195
C (4)	-0.116317
C (5)	-0.127964
C (6)	-0.136589
N (7)	-0.666559
C (8)	-0.021606
S (9)	0.389213
C (10)	-0.398432
C (11)	-0.126978
C (12)	0.256463
C (13)	-0.088983
C (14)	-0.113315
N (15)	0.035632
O (16)	-0.244300
O (17)	-0.253843
C (18)	0.141860
O (19)	-0.406723
H (20)	0.148315
H (21)	0.183887
H (22)	0.141411
H (23)	0.320414
H (24)	0.199655
H (25)	0.208490
H (26)	0.214348
H (27)	0.161827
H (28)	0.200550
H (29)	0.111776

Table-6: In-vitro Analysis of Anti-cancer Activity

S.NO	Compound code	name of drug concentration	initial weight(gm)	Weight at		Drainradial length		No. of Seeds germinated		% of seed germination	
				T0(gms)	T48(gms)	T0(cm)	T48(cm)	T0	T48	T0	T48
1	PTZ-I	100µg/ml	1.52	3.52	3.98	0.89	0.98	9	11	45%	55%
		200µg/ml	1.55	3.92	4.68	0.85	0.91	8	11	40%	55%
		300µg/ml	1.54	3.12	4.02	0.84	0.95	9	10	45%	50%
		400µg/ml	1.56	3.35	3.46	0.85	0.94	9	11	40%	50%
		500µg/ml	1.58	3.16	3.55	0.84	0.96	8	10	45%	55%
2	PTZ-II	100µg/ml	1.56	3.82	4.72	1.02	1.18	10	11	50%	55%
		200µg/ml	1.56	3.64	4.32	0.52	0.58	7	9	35%	45%
		300µg/ml	1.54	3.42	4.12	0.58	0.62	6	8	30%	40%
		400µg/ml	1.54	3.44	4.15	0.57	0.54	8	8	35%	45%
		500µg/ml	1.57	3.55	4.20	0.54	0.60	7	7	30%	40%
3	PTZ-III	100µg/ml	1.56	3.52	4.32	1.05	0.98	9	11	45%	40%
		200µg/ml	1.54	3.54	4.21	0.82	0.97	9	9	40%	55%
		300µg/ml	1.55	3.4648	4.39	0.91	1.02	8	8	40%	55%
		400µg/ml	1.55	3.55	4.40	0.95	1.05	7	8	40%	45%
		500µg/ml	1.59	3.48	4.48	0.95	1.04	8	8	45%	55%

4	PTZ-IV	100µg/ml	1.52	2.73	3.93	1.32	0.82	10	11	50%	50%
		200µg/ml	1.54	3.07	4.02	1.25	0.91	11	11	55%	60%
		300µg/ml	1.54	3.13	4.29	1.12	0.82	9	10	45%	65%
		400µg/ml	1.52	3.15	4.18	1.10	0.84	8	10	45%	60%
		500µg/ml	1.55	3.25	4.12	1.08	0.88	9	11	55%	50%
5	PTZ-V	100µg/ml	1.55	3.09	3.99	0.98	0.91	10	12	50%	55%
		200µg/ml	1.52	3.22	4.02	1.06	1.32	8	13	40%	60%
		300µg/ml	1.52	3.13	4.29	1.12	1.25	9	11	45%	55%
		400µg/ml	1.56	3.18	4.08	1.16	1.12	8	11	50%	55%
		500µg/ml	1.53	3.23	4.33	1.14	1.26	8	10	55%	50%
6	standard	100µg/ml	1.56	3.42	4.32	0.52	0.58	7	9	35%	45%
		200µg/ml	1.54	3.64	4.12	0.58	0.61	6	8	45%	40%
		300µg/ml	1.56	3.42	4.02	0.61	1.05	7	9	30%	55%
		400µg/ml	1.53	3.44	4.99	0.50	1.00	6	9	30%	55%
		500µg/ml	1.54	3.68	4.06	0.66	0.8	7	8	35%	50%

Table-7: *In-vitro* Analysis of Anti-inflammatory Activity

S.No	Name of the Compounds	Absorbance Value (Mean)	% Inhibition
1	PTZ-I	1.564	50.9
2	PTZ-II	1.904	92.1
3	PTZ-III	1.826	57.9
4	PTZ-IV	1.753	56.2
5	PTZ-V	1.650	53.4
6	STANDARD	0.142	89.5
7	CONTROL	0.265	0

Table-8: *In-vitro* Analysis of Anti-oxidant Activity

S.No	Name of the Compounds	Absorbance Value (Mean)	% Inhibition
1	PTZ-I	0.3040	59.0
2	PTZ-II	0.2208	70.2
3	PTZ-III	0.4726	36.4
4	PTZ-IV	0.4934	33.5
5	PTZ-V	0.1402	81.1
6	Standard	0.7678	86.4
7	control	0.5665	0

4. RESULTS

Compounds synthesized were screened for anti-Cancer activity. The length of the used Mung beans are measured at regular intervals. Among all the screened compounds PTZ-3&PTZ-4 had shown potent activity compared to standard. Compounds synthesized were screened for Anti-inflammatory activity using inhibition of albumin denaturation and then turbidity was measure

at 240nm. Among all the screened compounds PTZ-II had shown the potent a activity compared to standard. Compounds synthesized were screened for Anti-oxidant activity among all the screened compounds PTZ-V had shown the potent a activity compared to standard. Perform the molecular docking studies for anti-Cancer activity using AutoDock Software, kDM5 is collected from protein data bank.




Figure-1: PTZ-1




Figure-2: PTZ-2




Figure-3: PTZ-3




Figure-4: PTZ-4




Figure-5: PTZ-5

IR Spectral Studies:




Figure-6: IR Spectroscopy for PTZ-1




Figure-7: IR Spectroscopy for PTZ-2




Figure-8: IR Spectroscopy for PTZ-3




Figure-9: IR Spectroscopy for PTZ-4




Figure-10: IR Spectroscopy for PTZ-5

NMR spectral studies




Figure-11: ¹H NMR Spectroscopy for PTZ-1




Figure-15: ¹H NMR Spectroscopy for PTZ-3




Figure-16: ¹³C NMR Spectroscopy for PTZ-3




Figure-17: ¹H NMR Spectroscopy for PTZ-4




Figure-18: C NMR Spectroscopy for PTZ-4




Figure-19: ¹H NMR Spectroscopy for PTZ-5






Figure-20: C NMR Spectroscopy for PTZ-5


HOMO LUMO Results:



HOMO = -0.22290Ha = -6.065eV



LUMO = -0.12589Ha = -3.426eV



Band Gap Energy (Ha) = 0.0884351 = 2.406 eV

Figure-21 DFT Energy calculations




Figure-22: In-Vitro Anti-cancer activity




Figure-23: In-Vitro Anti-Inflammatory activity




Figure-24: *In-Vitro* Anti-Oxidant activity

5. DISCUSSION

In the present study, Novel 9,10 phenothiazine derivatives were synthesized and characterized by TLC, IR, NMR and Mass spectroscopic data. All synthesized (PTZ-1 to PTZ-5) were screened for Docking studies and also for *in-vitro* Anti Cancer, Anti-oxidant and Anti-Inflammatory. Molecular docking studies of title compounds for Anti Cancer Activity using Buffer and Aspirin as standard, (5ive) had shown the compounds PTZ-3, PTZ-4, PTZ-5, PTZ-1, PTZ-2 were potent compared to standard and other title compounds.

Evaluation of *in-vitro* anti-inflammatory activity was screened for synthesized compounds using Ibuprofen as standard and (COX-II) had shown the compounds PTZ-2, PTZ-3, PTZ-4, PTZ-5, PTZ-1 were potent compared to standard and other title compounds. Evaluation of *in-vitro* anti-oxidant activity was screened for synthesized compounds using ascorbic acid as standard. PTZ-5, PTZ-2, PTZ-1, PTZ-3, PTZ-4 had shown the significant activity.

6. CONCLUSION

From this study, it is concluded that 9,10 substituted phenothiazine derivatives incorporation of various halogenated compounds at 1,2&3 positions and cyclization with sulfur to the benzaldehyde would produce new compounds with potent biological activities like anti cancer, anti-inflammatory and anti-oxidant Activity. All the synthesized compounds would deserve for further advanced investigation and will be perform *in-vivo* studies for anti-cancer, anti-inflammatory and anti-oxidant.

LIST OF ABBREVIATIONS

PTZ- Phenothiazine

NMR- Nuclear magnetic resonance

IR- Infrared spectroscopy

kDM5- Lysine-specific demethylase 5A

HOMO-Highest occupied molecular orbital

LUMO- Lowest unoccupied molecular orbital

ACKNOWLEDGMENT

My special thanks to Hindu college of pharmacy, Guntur and Department of pharmaceutical chemistry for providing infrastructure and facilities for this research.

CONFLICT OF INTEREST

The authors have no conflicts of interest regarding this investigation.

REFERENCES

- Dinesh, Kumar, Arya. & Asha, Verma. (2013). A Review on pharmacological or biological activities of different derivatives phenothiazine, 2(2). DOI: <https://doi.org/10.1016/j.ipha.2023.06.001>
- Ting, Ting, Zhao. & Chuanbodai. (2018). Research progress of phenothiazine compounds of Dioxopromethazinehydrochloride, 1, 183-186. DOI:10.26480/icnmim.01.2018.183.186
- Dai, C., Sun, X., Tu, X., Wu, L., Zhan, D., & Zeng, Q. (2012). Synthesis of phenothiazines via ligand-free CuI-catalyzed cascade C–S and C–N coupling of aryl ortho-dihalides and ortho-aminobenzenethiols. *Chemical Communications*, 48(43), 5367-5369. DOI:10.1039/c2cc30814b
- Venkatesan, Kasi. & V. S. Vsatyanarayana, (2022). Synthesis and biological evaluation of novel Phenothiazines derivatives as potential antitumour agents. 42. DOI: <https://doi.org/10.1080/14756366.2016.1205046>
- Dighe, N. S., Barhate, R. N., Lawre, R. B., & Nirmal, S. A. (2015). Synthesis and Evaluation of

- Phenothiazine derivative for Anti-depressant activity. *Asian Journal of Research in Chemistry*, 8(12), 745-750.
- Mayer, M., Lang, P. T., Gerber, S., Madrid, P. B., Pinto, I. G., Guy, R. K., & James, T. L. (2006). Synthesis and testing of a focused phenothiazine library for binding to HIV-1 TAR RNA. *Chemistry & biology*, 13(9), 993-1000.
 - Venkatesan, K., Satyanarayana, V. S. V., & Sivakumar, A. (2018). Efficient Synthesis of Phenothiazine-based Heterocyclic Derivatives and their Biological Studies. *Indian Journal of Heterocyclic Chemistry*, 28(3), 367-372.
 - Tepe, B., Sokmen, M., Akpulat, H. A., & Sokmen, A. (2006). Screening of the antioxidant potentials of six *Salvia* species from Turkey. *Food chemistry*, 95(2), 200-204.
 - Sharma, S., Srivastava, V. K., & Kumar, A. (2005). Synthesis and anti-inflammatory activity of some heterocyclic derivatives of phenothiazine. *Die Pharmazie-An International Journal of Pharmaceutical Sciences*, 60(1), 18-22.
 - Kalkanidis, M., Klonis, N., Tilley, L., & Deady, L. W. (2002). Novel phenothiazine antimalarials: synthesis, antimalarial activity, and inhibition of the formation of β -haematin. *Biochemical pharmacology*, 63(5), 833-842.
 - Motohashi, N., Kawase, M., Satoh, K., & Sakagami, H. (2006). Cytotoxic potential of phenothiazines. *Current Drug Targets*, 7(9), 1055-1066.
 - Chandra, Vadivelu. Gopi. (2019). Recent Progress in Synthesis, Structure and Biological Activities of Phenothiazine Derivatives, *Review Journal of Chemistry*, 9(2), 95-126.
 - Arya, D. K., Verma, A., Singh, D., & Kachhawa, J. B. S. (2013). A review on pharmacological/biological activities of different derivatives of phenothiazines. *International Journal of Environment & Animal Conservation*, 2, 24-31.
 - Venkatesan, K., Satyanarayana, V. S. V., Mohanapriya, K., Khora, S. S., & Sivakumar, A. (2015). Ultrasound-mediated synthesis of phenothiazine derivatives and their in vitro antibacterial and antioxidant studies. *Research on Chemical Intermediates*, 41, 595-607.
 - García-Báez, E. V., Padilla-Martínez, I. I., Tamay-Cach, F., & Cruz, A. (2021). Benzothiazoles from condensation of o-aminothiophenoles with carboxylic acids and their derivatives: A review. *Molecules*, 26(21), 6518.
 - Dr. Konda, Ravi. Kumar. (2019). Synthesis, Characterization and In-vitro Anti-Inflammatory Activity of Phenothiazine Derivatives, 2019 10(1).
 - Dighe, N. S., Shinde, P. S., Vikhe, S. B., Dighe, S. B., & Musmade, D. S. (2015). QSAR study, synthesis and anti-depressant studies of some novel schiff base derivatives of benzothiazepine. *Bulgarian Chemical Communication*, 47(3), 837-843.
 - Abuhaie, C. M., Bîcu, E., Rigo, B., Gautret, P., Belei, D., Farce, A., ... & Ghinet, A. (2013). Synthesis and anticancer activity of analogues of phenstatin, with a phenothiazine A-ring, as a new class of microtubule-targeting agents. *Bioorganic & medicinal chemistry letters*, 23(1), 147-152.
 - Darvesh, S., McDonald, R. S., Penwell, A., Conrad, S., Darvesh, K. V., Mataija, D., ... & Martin, E. (2005). Structure-activity relationships for inhibition of human cholinesterases by alkyl amide phenothiazine derivatives. *Bioorganic & medicinal chemistry*, 13(1), 211-222.
 - SMITH, N. L. (1951). Formation and oxidation of some phenothiazine derivatives. *The Journal of Organic Chemistry*, 16(3), 415-418.
 - Chavan, A. A., & Pai, N. R. (2007). Synthesis and biological activity of N-substituted-3-chloro-2-azetidiones. *Molecules*, 12(11), 2467-2477.
 - Chavan, A. A., & Pai, N. R. (2007). Synthesis and biological activity of N-substituted-3-chloro-2-azetidiones. *Molecules*, 12(11), 2467-2477.
 - Silva, G. A., Costa, L. M., Brito, F. C., Miranda, A. L., Barreiro, E. J., & Fraga, C. A. (2004). New class of potent antinociceptive and antiplatelet 10H-phenothiazine-1-acylhydrazone derivatives. *Bioorganic & medicinal chemistry*, 12(12), 3149-3158.
 - Sarmiento, G. P., Vitale, R. G., Afeltra, J., Moltrasio, G. Y., & Moglioni, A. G. (2011). Synthesis and antifungal activity of some substituted phenothiazines and related compounds. *European journal of medicinal chemistry*, 46(1), 101-105.
 - 25. Ghinet, A., Moise, I.M., Rigo, B., Homerin, G., Farce, A., Dubois, J., & Bîcu, E., *Bioorg. Med. Chem.* (2016), vol. 24, no. 10, p. 2307.
 - 26. Maddila, S., Momin, M., Gorle, S., Palakondur, L., & Jonnalagadda, S.B., *J. Chil. Chem. Soc.* (2015), vol. 60, no. 1, p. 2919.
 - Yamamura, T., Suzuki, K., Yamaguchi, T., & Nishiyama, T. (1997). Antioxidant Activities of Phenothiazines and Related Compounds: Correlation between the Antioxidant Activities and Dissociation Energies of OH or NH Bonds. *Bulletin of the chemical society of Japan*, 70(2), 413-419.
 - Wu, S., Hu, W. Y., & Zhang, S. L. (2016). Potassium carbonate-mediated tandem C-S and C-N coupling reaction for the synthesis of phenothiazines under transition-metal-free and ligand-free conditions. *RSC advances*, 6(29), 24257-24260.
 - Abu-Abdoun, I. I., & Ledwith, A. (1997). Cationic polymerization photochemically and thermally induced by phenothiazine cation radical salts. *European polymer journal*, 33(10-12), 1671-1677.
 - Reddyrajula, R., Dalimba, U., & Kumar, S. M. (2019). Molecular hybridization approach for phenothiazine incorporated 1, 2, 3-triazole hybrids as promising antimicrobial agents: Design, synthesis, molecular docking and in silico ADME

- studies. *European Journal of Medicinal Chemistry*, 168, 263-282.
- Ramprasad, J., Nayak, N., & Dalimba, U. (2015). Design of new phenothiazine-thiadiazole hybrids via molecular hybridization approach for the development of potent antitubercular agents. *European Journal of Medicinal Chemistry*, 106, 75-84.
 - Kubota, K., Kurebayashi, H., Miyachi, H., Tobe, M., Onishi, M., & Isobe, Y. (2009). Synthesis and structure-activity relationships of phenothiazine carboxylic acids having pyrimidine-dione as novel histamine H1 antagonists. *Bioorganic & medicinal chemistry letters*, 19(10), 2766-2771.
 - Ohlow, M. J., & Moosmann, B. (2011). Phenothiazine: the seven lives of pharmacology's first lead structure. *Drug discovery today*, 16(3-4), 119-131.
 - Choudhary, S., Singh, P. K., Verma, H., Singh, H., & Silakari, O. (2018). Success stories of natural product-based hybrid molecules for multi-factorial diseases. *European journal of medicinal chemistry*, 151, 62-97.
 - DeEds, F., & Thomas, J. O. (1942). Studies on phenothiazine. XI. The excretion of phenothiazone. *The Journal of Parasitology*, 28(5), 363-367.
 - Manav, N., Verma, V., Pandey, V., Rather, H., Vasita, R., & Gupta, I. (2019). Synthesis and studies of phenothiazine based AIE fluorogens.
 - Gautam, N., Ajmera, N., Gupta, S., & Gautam, D. C. (2010). Synthesis, Spectral Characterization, and Biological Activity of Some New Substituted 10 H-Phenothiazines, Its Ribofuranosides, and Sulfones. *Nucleosides, Nucleotides and Nucleic Acids*, 29(3), 178-189.
 - Slattery, D. A., Hudson, A. L., & Nutt, D. J. (2004). Invited review: the evolution of antidepressant mechanisms. *Fundamental & clinical pharmacology*, 18(1), 1-21.
 - Ghinet, A., Moise, I. M., Rigo, B., Homerin, G., Farce, A., Dubois, J., & Bicu, E. (2016). Studies on phenothiazines: New microtubule-interacting compounds with phenothiazine A-ring as potent antineoplastic agents. *Bioorganic & Medicinal Chemistry*, 24(10), 2307-2317.
 - Dumitriu, G. M., Bicu, E., Belei, D., Rigo, B., Dubois, J., Farce, A., & Ghinet, A. (2015). Phenothiazine-based CaaX competitive inhibitors of human farnesyltransferase bearing a cysteine, methionine, serine or valine moiety as a new family of antitumoral compounds. *Bioorganic & Medicinal Chemistry Letters*, 25(20), 4447-4452.
 - Motohashi, N., Kawase, M., Saito, S., Kurihara, T., Satoh, K., Nakashima, H., ... & Molnár, J. (2000). Synthesis and biological activity of N-acylphenothiazines. *International Journal of Antimicrobial Agents*, 14(3), 203-207.
 - Kalkanidis, M., Klonis, N., Tilley, L., and Deady, L.W., *Biochem. Pharmacol.*, 2002, vol. 63, no. 1, p. 833.
 - Srivastava M., Salahuddin M.D., Shantakumar S.M. *E. J. Chem.* 2009;6:1055–1062.
 - Anjani K.T., Vinay K.S., Aruna B., Gauri S., Sweta S., Anil K.M. *Eur. J. Med. Chem.* 2007; 42:1234–1238.
 - Beniwal, M., Jain, N., Jain, S., & Aggarwal, N. (2022). Design, synthesis, anticancer evaluation and docking studies of novel 2-(1-isonicotinoyl-3-phenyl-1 H-pyrazol-4-yl)-3-phenylthiazolidin-4-one derivatives as Aurora-A kinase inhibitors. *BMC chemistry*, 16(1), 61.
 - Andreani, A., Rambaldi, M., Locatelli, A., Aresca, P., Bossa, R., & Galatulas, I. (1991). Potential antitumor agents XVIII (1). Synthesis and cytotoxic activity of phenothiazine derivatives. *European journal of medicinal chemistry*, 26(1), 113-116. DOI: 10.1016/0223-5234(91)90220-H.
 - Andreani, A.; Rambaldi, M.; Locatelli, A.; Aresca, P.; Bossa, R.; Galatulas, I. Potential antitumor agents XVIII (1). Synthesis and cytotoxic activity of phenothiazine derivatives. *Eur. J. Med. Chem.* 1991, 26, 113– 116, DOI: 10.1016/0223-5234(91)90220-H.
 - Rácz, B.; Spengler, G. Repurposing antidepressants and phenothiazine antipsychotics as efflux pump Inhibitors in cancer and infectious diseases. *Antibiotics* 2023, 12 (1), 137, DOI: 10.3390/antibiotics12010137.
 - Lopes, R. M.; Souza, A. C. S.; Otręba, M.; Rzepecka-Stojko, A.; Tersariol, I. L.; Rodrigues, T. Targeting autophagy by antipsychotic phenothiazines: potential drug repurposing for cancer therapy. *Biochem. Pharmacol.* 2024, 222, 116075, DOI: 10.1016/j.bcp.2024.116075.
 - Nagy, S.; Argyelan, G.; Molnar, J.; Kawase, M.; Motohashi, N. Antitumor activity of phenothiazine-related compounds. *Anticancer Res.* 1996, 16 (4A), 1915– 1918.
 - Ahmed M. Abdula, a Ahmad Fawzi Qarah, Design, synthesis, and molecular docking of new phenothiazine incorporated N-Mannich bases as promising antimicrobial agents, *Heliyon* v.10(7); (2024).
 - Venkatesan K. Satyanarayana V.S.V. Mohanapriya K. Khora S.S. Sivakumar A. Ultrasound-mediated synthesis of phenothiazine derivatives and their in vitro antibacterial and antioxidant studies. *Res. Chem. Intermediate.* 2015;41:595–607.
 - Jacob R.M. Robert, J. G. Ger. Pat. DE 1117584, 1961. Chem. Abstract. 1962;57.
 - Neuss N., Gorman M., Boaz H.E., Cone N.J. J. *Amer. Chem. Soc.* 1962;84:1509
 - Fernanda C. Domingues, Development of Phenothiazine Hybrids with Potential Medicinal Interest: A Review, doi: 10.3390/molecules27010276,(2022)

- Sachdeva T., Low M.L., Mai C., Cheong S.L., Liew Y.K., Milton M.D. Design, Synthesis and Characterisation of Novel Phenothiazine-Based Triazolopyridine Derivatives: Evaluation of Anti-Breast Cancer Activity on Human Breast Carcinoma. *Chemistry Select.* 2019;4:12701–12707. doi: 10.1002/slct.201903203.
- Takács, D., Egyed, O., Drahos, L., Szabó, P., Jemnitz, K., Szabó, M., ... & Hajós, G. (2013). Synthesis and pharmacological investigation of new N-hydroxyalkyl-2-aminophenothiazines exhibiting marked MDR inhibitory effect. *Bioorganic & medicinal chemistry*, 21(13), 3760-3779. doi: 10.1016/j.bmc.(2013).
- Montoya, M. C., DiDone, L., Heier, R. F., Meyers, M. J., & Krysan, D. J. (2017). Antifungal phenothiazines: optimization, characterization of mechanism, and modulation of neuroreceptor activity. *ACS infectious diseases*, 4(4), 499-507. doi:10.1021/acsinfecdis.7b00157.
- Louis DiDone 2, Richard F Heier ,Antifungal Phenothiazines: Optimization, Characterization of Mechanism, and Modulation of Neuroreceptor Activity, doi: 10.1021/acsinfecdis.7b00157,(2018).
- Benjamin A. Babalola, Monika Malik, Exploring the therapeutic potential of phenothiazine derivatives in medicinal chemistry, Volume 8 , June 2024, 101565.
- N. Naik, H.V. Kumar, V. Veena L.M. Nhari, E.N. Bifari, A.R. Al-Marhabi, F.A.M. Al-Zahrani, H.A. Al-Ghamdi, Synthesis of novel phenothiazine, phenoxazine and carbazole derivatives via Suzuki-Miyaura reaction *J. Organomet. Chem.*, 989 (2023), Article 122648.
- Andrei Zabulica a, Mihaela Balan, Novel luminescent phenothiazine-based Schiff bases with tuned morphology. Synthesis, structure, photophysical and thermotropic characterization, *Dyes and Pigments*, Volume 96, Issue 3 March 2013, Pages 686-698. Novel phenothiazine analogous: synthesis and a new perceptivity into their antioxidant potential *Pharm. Lett.*, 4 (3) (2012), pp. 786-794.
- Agata Jaszczyszyn ,Kazimierz Gąsiorowski ,Piotr wiątek, Chemical structure of phenothiazines and their biological activity, *Pharmacological Reports* Volume 64, Issue 1, January–February 2012, Pages 16-23.
- Krystian Pluta, Małgorzata Jelen, Anticancer activity of newly synthesized azaphenothiazines from NCI's anticancer screening bank, *Pharmacological Reports* Volume 62, Issue 2, March–April 2010, Pages 319-332.
- Rafal Korlacki ,Anticancer activities of tetra-, penta-, and hexacyclic phenothiazines modified with quinoline moiety. *Journal of Molecular Structure* ,Volume 1287, 5 September 2023, 135700.
- H. Sakagami, H. Takahashi, H. Yoshida, M. Yamamura, K. Fukuchi, K. Gomi, N. Motohashi, M. Takeda, Induction of DNA fragmentation in human Myelogenous Leukaemic cell lines by phenothiazine-related compounds, *Anticancer Res.*, 15 (1995), pp. 2533-2540.
- Y. Danyliv, O. Bezvikonnyi, D. Volyniuk, A. Lazauskas, J.V. Grazulevicius Reversibly switchable phase-dependent emission of quinoline and phenothiazine derivatives towards applications in optical sensing and information multicoding *Chem. Eur. J.*, 27 (2021), pp. 2826-2836.
- E.A. Onoabedje, S.A. Egu, M.A. Ezeokonkwo, U.C. Okoro, Highlights of molecular structures and applications of phenothiazine and phenoxazine polycycles, *J. Mol. Struct.*, 1175 (2019), pp. 956-962
- Yogajivan Rout, a Anupama Ekbote, Recent development on the synthesis, properties and applications of luminescent oxidized phenothiazine derivatives, *Journal of Materials Chemistry C*, (2021), 9 (24) , 7508-7531
- F.J. Rowell, S.M. Hui, J.W. Paxton. The evaluation of a radioimmunoassay for phenothiazines and S-thioxanthenes using an iodinated tracer. *Journal of Immunological Methods* 1979, 31 (1-2), 159-166.
- E.M. Hawes, M. Aravagiri, Radio-immunoassays for phenothiazine drugs and their major metabolites in plasma, *Progress in Neuro-Psychopharmacology and Biological Psychiatry*, Volume 7, Issues 4–6, 1983, Pages 709-714.
- C. M. Murphy and Harold Ravner, Mode of Action of Phenothiazine-Type Antioxidants, *nd. Eng. Chem.* (1950), 42, 12, 2479–2489.
- Farmer, L. A., Haidasz, E. A., Griesser, M., & Pratt, D. A. (2017). Phenoxazine: a privileged scaffold for radical-trapping antioxidants. *The Journal of organic chemistry*, 82(19), 10523-10536.
- Maxwell Gordon. Phenothiazines. 1967, 1-19 J. Cymerman Craig, M. E. Tate, G. P. Warwick, W. P. Rogers. Chemical Constitution and Anti-helminthic, Activity--IV. Substituted Phenothiazines. *Journal of Medicinal and Pharmaceutical Chemistry* 1960, 2 (6), 659-668.
- C.O. Okafor. The chemistry and applications of angular phenothiazine derivatives. *Dyes and Pigments* 1986, 7 (4), 249-287.
- Hussain, J., Angira, D., Hans, T., Dubey, P., Kirubakaran, S., & Thiruvengatam, V. (2020). Synthesis and characterization of a new class of phenothiazine molecules with 10H-substituted morpholine & piperidine derivatives: a structural insight. *Journal of Molecular Structure*, 1219, 128546.
- Johnson, D., Hussain, J., Bhoir, S., Chandrasekaran, V., Sahrawat, P., Hans, T., ... & Kirubakaran, S. (2023). Synthesis, kinetics and cellular studies of new phenothiazine analogs as potent human-TLK inhibitors. *Organic & Biomolecular Chemistry*, 21(9), 1980-1991.
- Sarett, L. H., Patchett, A. A., Steelman, S., Mellett, L. B., Woods, L. A., Schenker, E., ... & Herbst, H.

- (1963). *Phenothiazine und azaphenothiazine als heilmittel* (pp. 269-627). Birkhäuser Basel.
- Voronova, O., Zhuravkov, S., Korotkova, E., Artamonov, A., & Plotnikov, E. (2022). Antioxidant Properties of New Phenothiazine Derivatives. *Antioxidants*, 11(7), 1371.
 - Onoabedje, E. A., Okoro, U. C., & Knight, D. W. (2017). Rapid access to new angular phenothiazine and phenoxazine dyes. *Journal of Heterocyclic chemistry*, 54(1), 206-214.
 - L. R. Rudnick, Ed. Lubricant Additives Chemistry & Application, 2nd ed.; CRC Press, Taylor & Francis Group: USA, 2009, p 7.
 - Yunfengliao, Synthesis of phenothiazines from cyclohexanones and 2-aminobenzenethiol under transition metal free condition, *RSC Adv.*, 2013,3, 18605-18608
 - Y. Wei, I. Deb and N. Yoshikai, *J. Am. Chem. Soc.*, 2012, 134,9098.18608
 - Beresneva, T., & Abele, E. (2012). Novel copper-catalyzed rearrangement of 2-aminobenzothiazoles to phenothiazines. *Chemistry of Heterocyclic Compounds*, 48, 1420-1422.
 - Trivedi, A. R., Siddiqui, A. B., Dodiya, D. K., Soalnki, M. J., & Shah, V. H. (2009). A new synthetic approach and biological evaluation of novel phenothiazines bearing tert-butyl group. *Journal of Sulfur Chemistry*, 30(6), 590-595.
 - Qing-Hua Chen, Access to Phenothiazine Derivatives via Iodide-Mediated Oxidative Three-Component Annulation Reaction, *Journal of Organic Chemistry*, (2020)
 - T. Swager, A One-Step, Three-Component Reaction to Synthesize Phenothiazines, *Org. Chem.* 2020, 85, 5629–5637.
 - Tozer, T. N., & Tuck, L. D. (1965). Substituent effects on oxidation and stabilization of phenothiazine semiquinone free radicals. *Journal of Pharmaceutical Sciences*, 54(8), 1169-1175.
 - Erhard Von Schenker, Horst Herbst. Phenothiazine and Azophenothiazine also Heilmittel. 1963, 269-627
 - Bodea, C., & Silberg, I. (1968). Recent advances in the chemistry of phenothiazines. *Advances in heterocyclic chemistry*, 9, 321-460.
 - Chaudhary, S., Mukherjee, M., Paul, T. K., Bishnoi, S., Taraphder, S., & Milton, M. D. (2018). Novel Phenothiazine-5-oxide Based Push-Pull Molecules: Synthesis and Fine-Tuning of Electronic, Optical and Thermal Properties. *ChemistrySelect*, 3(18), 5073-5081.
 - Raval, K., & Ganatra, T. (2022). Basics, types and applications of molecular docking: A review. *IP International Journal of Comprehensive and Advanced Pharmacology*, 7(1), 12-16. [DOI:10.18231/j.ijcaap.2022.003]
 - Meng, X. Y., Zhang, H. X., Mezei, M., & Cui, M. (2011). Molecular docking: a powerful approach for structure-based drug discovery. *Current computer-aided drug design*, 7(2), 146-157.
 - Torres, P. H., Sodero, A. C., Jofily, P., & Silva-Jr, F. P. (2019). Key topics in molecular docking for drug design. *International journal of molecular sciences*, 20(18), 4574. [doi: 10.3390/ijms20184574]
 - Haluska, P., Dy, G. K., & Adjei, A. A. (2002). Farnesyl transferase inhibitors as anticancer agents. *European Journal of Cancer*, 38(13), 1685-1700. doi: 10.1016/S0959-8049(02)00166-1. - DOI – PubMed
 - Ghinet, A., Moise, I. M., Rigo, B., Homerin, G., Farce, A., Dubois, J., & Bicu, E. (2016). Studies on phenothiazines: New microtubule-interacting compounds with phenothiazine A-ring as potent antineoplastic agents. *Bioorganic & Medicinal Chemistry*, 24(10), 2307-2317. doi: 10.1016/j.bmc.2016.04.001. - DOI – PubMed
 - Padnya, P. L., Khadieva, A. I., & Stoikov, I. I. (2023). Current achievements and perspectives in synthesis and applications of 3, 7-disubstituted phenothiazines as Methylene Blue analogues. *Dyes and Pigments*, 208, 110806. doi: 10.1016/j.dyepig.2022.110806..
 - Patil, R. D., & Adimurthy, S. (2011). Copper-catalyzed aerobic oxidation of amines to imines under neat conditions with low catalyst loading. *Advanced Synthesis & Catalysis*, 353(10), 1695-1700.